• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

128
16
14
14
9

COUNTRY

14
1
1
1
1

PRICE

94
189
349
468

PUBLISHED

53
79
148
468

PRODUCT TYPE

413
41
10
4

Respiratory

Respiratory drugs and is a growing sector of the pharmaceuticals industry, and we have all the information resources that you need to be a leading player in this lucrative market. The publications listed under Research and Markets’ Respiratory category cover all drugs and therapeutics for conditions and diseases relating to the lungs and/or breathing, such as Acute Respiratory Distress Syndrome (ARDS), allergy, asthma, bronchitis, COPD (chronic obstructive pulmonary disease), cystic fibrosis, emphysema, lung disease, pneumonia, sinus infections, sleep apnea and others.

Our reports, books, and subscriptions will provide you with the latest industry news, forecasts, market trends and company profiles of market leaders and niche players including: Accentia Biopharmaceuticals, Aerogen, Aerovance, airPharma, AstraZeneca, Aventis Pharma, Bespak, Boehringer Ingelheim Pharmaceuticals, Cadila Pharmaceuticals, Dr. Reddys Laboratories, EvoGenix, GlaxoSmithKlineInyx, The Merck Generics Group, Novartis AG, Pfizer, Ranbaxy Laboratories, Respironics, Sandoz International, Schering-Plough, etc.

Publications on smoking cessation are listed under the OTC sub-category in the Pharmaceuticals section. Show Less
Read more

PRODUCT TITLE

Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014

Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014 Summary This, ‘Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014’, provides an overview of the Idiopathic Pulmonary Fibrosis’s therapeutic...

September 2014
FROM

OpportunityAnalyzer: Allergic Rhinitis: Allergen-Specific Immunotherapy - Opportunity Analysis and Forecast to 2018

OpportunityAnalyzer: Allergic Rhinitis: Allergen-Specific Immunotherapy - Opportunity Analysis and Forecast to 2018 Summary The global specific immunotherapy (SIT) market for allergic rhinitis (AR)...

September 2014
FROM

Bronchopulmonary Dysplasia - Pipeline Review, H2 2014

Bronchopulmonary Dysplasia - Pipeline Review, H2 2014 Summary This, ‘Bronchopulmonary Dysplasia - Pipeline Review, H2 2014’, provides an overview of the Bronchopulmonary Dysplasia’s therapeutic pipeline. This...

September 2014
FROM

EpiCast Report: Asthma - Epidemiology Forecast to 2023

EpiCast Report: Asthma - Epidemiology Forecast to 2023 Summary Asthma is a chronic inflammatory lung disease that affects persons of all ages, but most commonly starts in childhood. It is a common...

September 2014
FROM

Chronic Cough - Pipeline Review, H2 2014

Chronic Cough - Pipeline Review, H2 2014 Summary This, ‘Chronic Cough - Pipeline Review, H2 2014’, provides an overview of the Chronic Cough’s therapeutic pipeline. This report provides comprehensive...

September 2014
FROM

Cough - Pipeline Review, H2 2014

Cough - Pipeline Review, H2 2014 Summary This, ‘Cough - Pipeline Review, H2 2014’, provides an overview of the Cough’s therapeutic pipeline. This report provides comprehensive information on the...

August 2014
FROM

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2014

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2014 Summary This, ‘Acute Respiratory Distress Syndrome - Pipeline Review, H2 2014’, provides an overview of the Acute Respiratory Distress...

August 2014
FROM

PharmaPoint: Asthma - Japan Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - Japan Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented...

August 2014
FROM

PharmaPoint: Asthma - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - 5EU Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented...

August 2014
FROM

PharmaPoint: Asthma - Current and Future Players

PharmaPoint: Asthma - Current and Future Players Summary The publisher has released its pharma report, “PharmaPoint: Asthma - Current and Future Players”. The report is a vital source of up-to-date...

August 2014
FROM

PharmaPoint: Asthma - Australia Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - Australia Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily...

August 2014
FROM

Dulera (Asthma) - Forecast and Market Analysis to 2023

Dulera (Asthma) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Dulera (Asthma) - Forecast and Market Analysis to 2023”. The...

August 2014
FROM

Xolair (Asthma) - Forecast and Market Analysis to 2023

Xolair (Asthma) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Xolair (Asthma) - Forecast and Market Analysis to 2023”. The...

August 2014
FROM

Symbicort (Asthma) - Forecast and Market Analysis to 2023

Symbicort (Asthma) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Symbicort (Asthma) - Forecast and Market Analysis to 2023”....

August 2014
FROM

Fluticasone Furoate (Asthma) - Forecast and Market Analysis to 2023

Fluticasone Furoate (Asthma) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Fluticasone Furoate (Asthma) - Forecast and Market...

August 2014
FROM

Advair (Asthma) - Forecast and Market Analysis to 2023

Advair (Asthma) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Advair (Asthma) - Forecast and Market Analysis to 2023”. The...

August 2014
FROM

Fostair (Asthma) - Forecast and Market Analysis to 2023

Fostair (Asthma) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Fostair (Asthma) - Forecast and Market Analysis to 2023”. The...

August 2014
FROM

Spiriva (Asthma) - Forecast and Market Analysis to 2023

Spiriva (Asthma) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Spiriva (Asthma) - Forecast and Market Analysis to 2023”. The...

August 2014
FROM

Flutiform (Asthma) - Forecast and Market Analysis to 2023

Flutiform (Asthma) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Flutiform (Asthma) - Forecast and Market Analysis to 2023”....

August 2014
FROM

Tralokinumab (Asthma) - Forecast and Market Analysis to 2023

Tralokinumab (Asthma) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Tralokinumab (Asthma) - Forecast and Market Analysis to...

August 2014
FROM
Loading Indicator

Our Clients

Sanofi S.A. GlaxoSmithKline PLC Astrazeneca PLC Invacare Corporation Boehringer Ingelheim GmbH Takeda Pharmaceutical Company Limited